{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:42:25Z","timestamp":1790131345958,"version":"4.0.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04175-7","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:13:30Z","timestamp":1770138810000},"page":"2449-2467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials"],"prefix":"10.1007","volume":"28","author":[{"given":"Lang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasur","family":"Rizaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled Fahmi","family":"Fawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa jawad","family":"kadham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabieva","family":"Dildora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakhlokhon","family":"Kurbanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zamira","family":"Atamuratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asilbek","family":"Dauletbaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natrayan","family":"Lakshmaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7543-4020","authenticated-orcid":false,"given":"Raed Fanoukh Aboqader","family":"Al-Aouadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"3","key":"4175_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4175_CR2","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1186\/s12885-024-13141-5","volume":"24","author":"H Zhang","year":"2024","unstructured":"Zhang H, Yang W, Tan X, He W, Zhao L, Liu H, et al. Long-term relative survival of patients with gastric cancer from a large-scale cohort: a period-analysis. BMC Cancer. 2024;24(1):1420. https:\/\/doi.org\/10.1186\/s12885-024-13141-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"4175_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","volume":"44","author":"SH Zhang","year":"2024","unstructured":"Zhang SH, Peng LL, Chen YF, Xu Y, Moradi V. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy. Inflamm Regen. 2024;44(1):45. https:\/\/doi.org\/10.1186\/s41232-024-00358-x.","journal-title":"Inflamm Regen"},{"key":"4175_CR4","unstructured":"AUCATZYL 2024. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl"},{"issue":"10","key":"4175_CR5","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1016\/j.ymthe.2024.09.015","volume":"32","author":"N Singh","year":"2024","unstructured":"Singh N. Approval of the first TCR-based cell therapy. Mol Ther. 2024;32(10):3195. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.015.","journal-title":"Mol Ther"},{"key":"4175_CR6","unstructured":"FDA approves first cellular therapy to treat patients with unresectable or metastatic melanoma 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma"},{"issue":"5","key":"4175_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"issue":"7","key":"4175_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10(7):627\u201342. https:\/\/doi.org\/10.1016\/j.trecan.2024.03.008.","journal-title":"Trends Cancer"},{"issue":"1","key":"4175_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"key":"4175_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1487782","author":"J Li","year":"2024","unstructured":"Li J, Zhang Y, Fu T, Xing G, Cai H, Li K, et al. Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1487782.","journal-title":"Front Immunol"},{"issue":"6","key":"4175_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jcyt.2020.01.012","volume":"22","author":"MJ Fontaine","year":"2020","unstructured":"Fontaine MJ, Selogie E, Stroncek D, McKenna D, Szczepiorkowski ZM, Takanashi M, et al. Variations in novel cellular therapy products manufacturing. Cytotherapy. 2020;22(6):337\u201342. https:\/\/doi.org\/10.1016\/j.jcyt.2020.01.012.","journal-title":"Cytotherapy"},{"key":"4175_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007959","author":"X Li","year":"2024","unstructured":"Li X, Zhou Y, Xu B, Qin Y, Zhao J, Li M, et al. Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1\/PD-L1 inhibitors. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-007959.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4175_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"5","key":"4175_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"1","key":"4175_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med. 2025;23(1):10. https:\/\/doi.org\/10.1186\/s12967-024-06052-3.","journal-title":"J Transl Med"},{"key":"4175_CR16","doi-asserted-by":"publisher","first-page":"1500177","DOI":"10.3389\/fimmu.2024.1500177","volume":"15","author":"KMN Farid","year":"2024","unstructured":"Farid KMN, Bug G, Schmitt A, Lang F, Schubert ML, Haberkorn U, et al. GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation\u2014successfully treated by extracorporeal photopheresis. Front Immunol. 2024;15:1500177. https:\/\/doi.org\/10.3389\/fimmu.2024.1500177.","journal-title":"Front Immunol"},{"issue":"10389","key":"4175_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"4175_CR18","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"10494","key":"4175_CR19","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405(10494):2049\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8.","journal-title":"Lancet"},{"issue":"4","key":"4175_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409\u201318. https:\/\/doi.org\/10.1093\/jnci\/djy134.","journal-title":"J Natl Cancer Inst"},{"issue":"15 suppl","key":"4175_CR21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","volume":"37","author":"X Zhan","year":"2019","unstructured":"Zhan X, Wang B, Li Z, Li J, Wang H, Chen L, et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. J Clin Oncol. 2019;37(15 suppl):2509. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2509.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4175_CR22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"issue":"12","key":"4175_CR23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41416-025-03015-3","volume":"132","author":"J Li","year":"2025","unstructured":"Li J, Tao M, Liu L, Liu C, Ma M, Liu D, et al. Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer. Br J Cancer. 2025;132(12):1167\u201376. https:\/\/doi.org\/10.1038\/s41416-025-03015-3.","journal-title":"Br J Cancer"},{"key":"4175_CR24","doi-asserted-by":"publisher","first-page":"1182409","DOI":"10.3389\/fimmu.2023.1182409","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang L, Zhang Q, Shen J, Huang X, Wang M, et al. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma. Front Immunol. 2023;14:1182409.","journal-title":"Front Immunol"},{"issue":"3","key":"4175_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41416-020-0901-z","volume":"123","author":"J-P Lin","year":"2020","unstructured":"Lin J-P, Lin J-X, Ma Y-B, Xie J-W, Yan S, Wang J-B, et al. Prognostic significance of pre- and post-operative tumour markers for patients with gastric cancer. Br J Cancer. 2020;123(3):418\u201325. https:\/\/doi.org\/10.1038\/s41416-020-0901-z.","journal-title":"Br J Cancer"},{"issue":"8","key":"4175_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/2326-6066.Cir-24-0137","volume":"13","author":"Z Feng","year":"2025","unstructured":"Feng Z, Zhang X, Peng Z, Aghamajidi A, Wu Y, Hua X. Nanobody-directed CEA-targeting CAR T cells eliminate gastrointestinal cancer xenografts. Cancer Immunol Res. 2025;13(8):1160\u201371. https:\/\/doi.org\/10.1158\/2326-6066.Cir-24-0137.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"4175_CR27","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1002\/cam4.2361","volume":"8","author":"X Chi","year":"2019","unstructured":"Chi X, Yang P, Zhang E, Gu J, Xu H, Li M, et al. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Cancer Med. 2019;8(10):4753\u201365. https:\/\/doi.org\/10.1002\/cam4.2361.","journal-title":"Cancer Med"},{"issue":"1","key":"4175_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.Can-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu X, Chen J, Li W, Xu Y, Shan J, Hong J, et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 2024;84(1):84\u2013100. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-1038.","journal-title":"Cancer Res"},{"issue":"16 suppl","key":"4175_CR29","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1200\/JCO.2024.42.16_suppl.3514","volume":"42","author":"H Zhang","year":"2024","unstructured":"Zhang H, Yang Z, Zhu X, Li J, Gao Y, Zhang Y, et al. Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. J Clin Oncol. 2024;42(16 suppl):3514. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3514.","journal-title":"J Clin Oncol"},{"key":"4175_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091747","author":"T Kawakami","year":"2024","unstructured":"Kawakami T, Yamazaki K. Recent progress in treatment for HER2-positive advanced gastric cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16091747.","journal-title":"Cancers (Basel)"},{"key":"4175_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1080990","author":"C Ma","year":"2023","unstructured":"Ma C, Wang X, Guo J, Yang B, Li Y. Challenges and future of HER2-positive gastric cancer therapy. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1080990.","journal-title":"Front Oncol"},{"issue":"9742","key":"4175_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0140-6736(10)61121-x","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x.","journal-title":"Lancet"},{"issue":"10","key":"4175_CR33","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(18)30481-9.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4175_CR34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2217\/fon-2020-1007","volume":"17","author":"DV Catenacci","year":"2021","unstructured":"Catenacci DV, Rosales M, Chung HC, Yoon HH, Shen L, Moehler M, et al. MAHOGANY: margetuximab combination in HER2+ unresectable\/metastatic gastric\/gastroesophageal junction adenocarcinoma. Future Oncol. 2021;17(10):1155\u201364. https:\/\/doi.org\/10.2217\/fon-2020-1007.","journal-title":"Future Oncol"},{"issue":"10","key":"4175_CR35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","volume":"9","author":"Y Song","year":"2018","unstructured":"Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867\u201378. https:\/\/doi.org\/10.1007\/s13238-017-0384-8.","journal-title":"Protein Cell"},{"issue":"10","key":"4175_CR36","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","volume":"9","author":"K Feng","year":"2018","unstructured":"Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838\u201347. https:\/\/doi.org\/10.1007\/s13238-017-0440-4.","journal-title":"Protein Cell"},{"issue":"4 suppl","key":"4175_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/JCO.2025.43.4_suppl.449","volume":"43","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Li Q, Li W, Lu L, Xiao S, Cai Y, et al. Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies. J Clin Oncol. 2025;43(4 suppl):449. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.449.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4175_CR38","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"issue":"11","key":"4175_CR39","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919\u201329.","journal-title":"Mol Ther"},{"issue":"16","key":"4175_CR40","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.19.02085","volume":"38","author":"R Hassan","year":"2020","unstructured":"Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody\u2013drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020;38(16):1824\u201335.","journal-title":"J Clin Oncol"},{"key":"4175_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2023.100098","volume":"7","author":"S Saha","year":"2023","unstructured":"Saha S, Mukherjee C, Basak D, Panja P, Mondal PK, Ghosh R, et al. High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer. Adv Cancer Biol Metast. 2023;7:100098.","journal-title":"Adv Cancer Biol Metast"},{"key":"4175_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.245","volume-title":"Comprehensive characterization of mesothelin expression in colorectal cancer","author":"M Malla","year":"2023","unstructured":"Malla M, Deshmukh SK, Wu S, Xiu J, Farrell AP, Lenz H-J, et al. Comprehensive characterization of mesothelin expression in colorectal cancer. American Society of Clinical Oncology; 2023."},{"issue":"11","key":"4175_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70057","volume":"14","author":"S Mir","year":"2024","unstructured":"Mir S, Venugopalan A, Zhang J, Nair NU, Sengupta M, Khanal M, et al. Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. Clin Transl Med. 2024;14(11):e70057. https:\/\/doi.org\/10.1002\/ctm2.70057.","journal-title":"Clin Transl Med"},{"key":"4175_CR44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.omto.2021.02.013","volume":"20","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu G, Liu J, Yang M, Fu J, Liu G, et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Ther Oncolytics. 2021;20:556\u201368. https:\/\/doi.org\/10.1016\/j.omto.2021.02.013.","journal-title":"Mol Ther Oncolytics"},{"key":"4175_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660488","volume":"12","author":"R Zhao","year":"2021","unstructured":"Zhao R, Cui Y, Zheng Y, Li S, Lv J, Wu Q, et al. Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer. Front Immunol. 2021;12:660488. https:\/\/doi.org\/10.3389\/fimmu.2021.660488.","journal-title":"Front Immunol"},{"issue":"7","key":"4175_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 2019;10(7):476. https:\/\/doi.org\/10.1038\/s41419-019-1711-1.","journal-title":"Cell Death Dis"},{"key":"4175_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47020123","author":"C-H Chang","year":"2025","unstructured":"Chang C-H, Tsai C-C, Tsai F-M, Chu T-Y, Hsu P-C, Kuo C-Y. EpCAM signaling in oral cancer stem cells: implications for metastasis, tumorigenicity, and therapeutic strategies. Curr Issues Mol Biol. 2025. https:\/\/doi.org\/10.3390\/cimb47020123.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"4175_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41419-017-0013-8","volume":"9","author":"M-H Wang","year":"2018","unstructured":"Wang M-H, Sun R, Zhou X-M, Zhang M-Y, Lu J-B, Yang Y, et al. Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN\/AKT\/mTOR pathway. Cell Death Dis. 2018;9(1):2. https:\/\/doi.org\/10.1038\/s41419-017-0013-8.","journal-title":"Cell Death Dis"},{"issue":"4","key":"4175_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175357","volume":"12","author":"M Dai","year":"2017","unstructured":"Dai M, Yuan F, Fu C, Shen G, Hu S, Shen G. Relationship between epithelial cell adhesion molecule (EpCAM) overexpression and gastric cancer patients: a systematic review and meta-analysis. PLoS ONE. 2017;12(4):e0175357.","journal-title":"PLoS ONE"},{"key":"4175_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235552","author":"Y Yang","year":"2023","unstructured":"Yang Y, Louie R, Puc J, Vedvyas Y, Alcaina Y, Min IM, et al. Chimeric antigen receptor T cell therapy targeting epithelial cell adhesion molecule in gastric cancer: mechanisms of tumor resistance. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15235552.","journal-title":"Cancers (Basel)"},{"key":"4175_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.08.014","author":"W Fang","year":"2025","unstructured":"Fang W, Lu Z, Ge J, Zhang S, Zheng R, Yin W, et al. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.014.","journal-title":"Mol Ther"},{"issue":"48","key":"4175_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li D, Guo X, Yang K, Yang Y, Zhou W, Huang Y, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9(48):eadg9721. https:\/\/doi.org\/10.1126\/sciadv.adg9721.","journal-title":"Sci Adv"},{"key":"4175_CR53","doi-asserted-by":"publisher","first-page":"1557644","DOI":"10.3389\/fimmu.2025.1557644","volume":"16","author":"J Han","year":"2025","unstructured":"Han J, Wang Y, Chan GC-F, Chan WK. Designs of NKG2D-based immunotherapeutics for cancer. Front Immunol. 2025;16:1557644.","journal-title":"Front Immunol"},{"issue":"18","key":"4175_CR54","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2217\/fon-2017-0102","volume":"13","author":"B Demoulin","year":"2017","unstructured":"Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman M-L, Lonez C, et al. Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncol. 2017;13(18):1593\u2013605.","journal-title":"Future Oncol"},{"issue":"5","key":"4175_CR55","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-018-3670-0","volume":"82","author":"K Tao","year":"2018","unstructured":"Tao K, He M, Tao F, Xu G, Ye M, Zheng Y, et al. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharmacol. 2018;82(5):815\u201327.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"4175_CR56","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1111\/cas.15828","volume":"114","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liang K, Zhou X, Zhang X, Xu H, Dai H, et al. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. Cancer Sci. 2023;114(7):2798\u2013809. https:\/\/doi.org\/10.1111\/cas.15828.","journal-title":"Cancer Sci"},{"key":"4175_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01066-5","author":"M Sun","year":"2025","unstructured":"Sun M, Bian L, Wang H, Liu X, Li Y, Wu Z, et al. Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor. Cell Oncol (Dordr). 2025. https:\/\/doi.org\/10.1007\/s13402-025-01066-5.","journal-title":"Cell Oncol (Dordr)"},{"key":"4175_CR58","doi-asserted-by":"publisher","first-page":"1511931","DOI":"10.3389\/fcell.2024.1511931","volume":"12","author":"F Dehghan","year":"2024","unstructured":"Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V. Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy. Front Cell Dev Biol. 2024;12:1511931.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"4175_CR59","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/trf.14003","volume":"57","author":"ES Allen","year":"2017","unstructured":"Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017;57(5):1133\u201341. https:\/\/doi.org\/10.1111\/trf.14003.","journal-title":"Transfusion"},{"key":"4175_CR60","doi-asserted-by":"publisher","first-page":"1192907","DOI":"10.3389\/fimmu.2023.1192907","volume":"14","author":"E Shin","year":"2023","unstructured":"Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, et al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond. Front Immunol. 2023;14:1192907. https:\/\/doi.org\/10.3389\/fimmu.2023.1192907.","journal-title":"Front Immunol"},{"key":"4175_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N. The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials. Biomed Pharmacother. 2023;169:115888. https:\/\/doi.org\/10.1016\/j.biopha.2023.115888.","journal-title":"Biomed Pharmacother"},{"key":"4175_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155518","volume":"262","author":"C Tang","year":"2024","unstructured":"Tang C, Zhang Y. Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: a comprehensive review. Pathol Res Pract. 2024;262:155518. https:\/\/doi.org\/10.1016\/j.prp.2024.155518.","journal-title":"Pathol Res Pract"},{"issue":"14","key":"4175_CR63","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.7150\/ijbs.64630","volume":"17","author":"B Cao","year":"2021","unstructured":"Cao B, Liu M, Huang J, Zhou J, Li J, Lian H, et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci. 2021;17(14):3850\u201361. https:\/\/doi.org\/10.7150\/ijbs.64630.","journal-title":"Int J Biol Sci"},{"key":"4175_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000450","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000450.","journal-title":"J Immunother Cancer"},{"key":"4175_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3152","author":"TE Seery","year":"2020","unstructured":"Seery TE, Kistler M, Lee JH, Soon-Shiong P. Quilt-3.064: an open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS3152.","journal-title":"J Clin Oncol"},{"key":"4175_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635173","volume":"12","author":"S Chen","year":"2021","unstructured":"Chen S, Lai SW, Brown CE, Feng M. Harnessing and enhancing macrophage phagocytosis for cancer therapy. Front Immunol. 2021;12:635173.","journal-title":"Front Immunol"},{"issue":"1","key":"4175_CR67","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1146\/annurev-immunol-032414-112220","volume":"33","author":"C Varol","year":"2015","unstructured":"Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33(1):643\u201375.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"4175_CR68","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81(5):1201\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"4175_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"issue":"1","key":"4175_CR70","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","volume":"16","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Zhu T, Chen Z, Huang X. Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles. Nat Commun. 2025;16(1):7166. https:\/\/doi.org\/10.1038\/s41467-025-62506-2.","journal-title":"Nat Commun"},{"issue":"1","key":"4175_CR71","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16(1):706. https:\/\/doi.org\/10.1038\/s41467-024-55770-1.","journal-title":"Nat Commun"},{"issue":"3","key":"4175_CR72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","volume":"129","author":"X Dong","year":"2023","unstructured":"Dong X, Fan J, Xie W, Wu X, Wei J, He Z, et al. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023;129(3):551\u201362. https:\/\/doi.org\/10.1038\/s41416-023-02319-6.","journal-title":"Br J Cancer"},{"issue":"1","key":"4175_CR73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13(1):76.","journal-title":"Exp Hematol Oncol"},{"key":"4175_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123300","volume":"361","author":"Y Shi","year":"2025","unstructured":"Shi Y, Li X, Dong Y, Yuan H, Wang Y, Yang R. Exploring the potential of CAR-macrophage therapy. Life Sci. 2025;361:123300.","journal-title":"Life Sci"},{"key":"4175_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109345","volume":"113","author":"L Wang","year":"2022","unstructured":"Wang L, Chen X, Zhang L, Niu B, Li L, Sun Y, et al. CAR cell design strategies in solid tumors. Int Immunopharmacol. 2022;113:109345.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"4175_CR76","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.molmed.2024.06.009","volume":"30","author":"L Yao","year":"2024","unstructured":"Yao L, Hatami M, Ma W, Skutella T. Vaccine-based immunotherapy and related preclinical models for glioma. Trends Mol Med. 2024;30(10):965\u201381. https:\/\/doi.org\/10.1016\/j.molmed.2024.06.009.","journal-title":"Trends Mol Med"},{"issue":"6230","key":"4175_CR77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"key":"4175_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13:835762. https:\/\/doi.org\/10.3389\/fimmu.2022.835762.","journal-title":"Front Immunol"},{"issue":"3","key":"4175_CR79","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.18632\/oncotarget.23469","volume":"9","author":"F Perea","year":"2018","unstructured":"Perea F, S\u00e1nchez-Palencia A, G\u00f3mez-Morales M, Bernal M, Concha \u00c1, Garc\u00eda MM, et al. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget. 2018;9(3):4120\u201333. https:\/\/doi.org\/10.18632\/oncotarget.23469.","journal-title":"Oncotarget"},{"issue":"10435","key":"4175_CR80","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D'Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Razak ARA, Agulnik M, Attia S, Blay J-Y, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371.","journal-title":"Lancet"},{"issue":"5","key":"4175_CR81","volume":"56","author":"X Zhao","year":"2024","unstructured":"Zhao X, Shao S, Hu L. The recent advancement of TCR-T cell therapies for cancer treatment: TCR-T cell therapies for cancer treatment. Acta Biochim Biophys Sin. 2024;56(5):663.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"4175_CR82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, et al. Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2023;29(1):104\u201314. https:\/\/doi.org\/10.1038\/s41591-022-02128-z.","journal-title":"Nat Med"},{"issue":"2","key":"4175_CR83","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1084\/jem.156.2.385","volume":"156","author":"TJ Eberlein","year":"1982","unstructured":"Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982;156(2):385\u201397. https:\/\/doi.org\/10.1084\/jem.156.2.385.","journal-title":"J Exp Med"},{"issue":"5","key":"4175_CR84","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","volume":"161","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Mul\u00e9 JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161(5):1169\u201388. https:\/\/doi.org\/10.1084\/jem.161.5.1169.","journal-title":"J Exp Med"},{"issue":"1","key":"4175_CR85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/bf00199837","volume":"24","author":"RL Kradin","year":"1987","unstructured":"Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, et al. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother. 1987;24(1):76\u201385. https:\/\/doi.org\/10.1007\/bf00199837.","journal-title":"Cancer Immunol Immunother"},{"key":"4175_CR86","doi-asserted-by":"publisher","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","volume":"13","author":"MH Kazemi","year":"2022","unstructured":"Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango? Front Immunol. 2022;13:1018962. https:\/\/doi.org\/10.3389\/fimmu.2022.1018962.","journal-title":"Front Immunol"},{"key":"4175_CR87","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v6.iSuppl3.79","author":"LCCZ Xu","year":"2000","unstructured":"Xu LCCZ, Sun ZH, Xu XY, Wu MS, Ding SB. Effect of treatment of tumor-infiltrating lymphocytes on gastric cancer. World J Gastroenterol. 2000. https:\/\/doi.org\/10.3748\/wjg.v6.iSuppl3.79.","journal-title":"World J Gastroenterol"},{"key":"4175_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114261","volume":"151","author":"A Jamal","year":"2025","unstructured":"Jamal A, Aldreiwish AD, Banawas SS, Alqurashi YE, Kamal MA, Ahmad F. The paths toward immunotherapy of esophageal cancer: an overview of clinical trials. Int Immunopharmacol. 2025;151:114261. https:\/\/doi.org\/10.1016\/j.intimp.2025.114261.","journal-title":"Int Immunopharmacol"},{"key":"4175_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298891","author":"M Piroozkhah","year":"2023","unstructured":"Piroozkhah M, Gholinezhad Y, Piroozkhah M, Shams E, Nazemalhosseini-Mojarad E. The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1298891.","journal-title":"Front Immunol"},{"key":"4175_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1358511","author":"MY Salnikov","year":"2024","unstructured":"Salnikov MY, MacNeil KM, Mymryk JS. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1358511.","journal-title":"Front Immunol"},{"issue":"32","key":"4175_CR91","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000011769","volume":"97","author":"JS Lee","year":"2018","unstructured":"Lee JS, Won HS, Sun S, Hong JH, Ko YH. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(32):e11769. https:\/\/doi.org\/10.1097\/md.0000000000011769.","journal-title":"Medicine (Baltimore)"},{"key":"4175_CR92","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18065","author":"X Zheng","year":"2017","unstructured":"Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q, et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.18065.","journal-title":"Oncotarget"},{"key":"4175_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1595070","author":"Z Yao","year":"2025","unstructured":"Yao Z, Li G, Pan D, Pei Z, Fang Y, Liu H, et al. Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1595070.","journal-title":"Front Immunol"},{"issue":"9","key":"4175_CR94","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41416-020-0793-y","volume":"122","author":"Y Kwak","year":"2020","unstructured":"Kwak Y, Koh J, Park Y, Hong YJ, Park KU, Kim HH, et al. Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. Br J Cancer. 2020;122(9):1399\u2013408. https:\/\/doi.org\/10.1038\/s41416-020-0793-y.","journal-title":"Br J Cancer"},{"issue":"11","key":"4175_CR95","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00262-019-02410-z","volume":"68","author":"Y Park","year":"2019","unstructured":"Park Y, Koh J, Kwak Y, Ahn SH, Park DJ, Kim HH, et al. Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer. Cancer Immunol Immunother. 2019;68(11):1779\u201390. https:\/\/doi.org\/10.1007\/s00262-019-02410-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"4175_CR96","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4149\/neo_2022_220128N123","volume":"69","author":"JS Yu","year":"2022","unstructured":"Yu JS, Huang WB, Zhang YH, Chen J, Li J, Fu HF, et al. The association of immune cell infiltration and prognostic value of tertiary lymphoid structures in gastric cancer. Neoplasma. 2022;69(4):886\u201398. https:\/\/doi.org\/10.4149\/neo_2022_220128N123.","journal-title":"Neoplasma"},{"issue":"1","key":"4175_CR97","doi-asserted-by":"publisher","first-page":"21530","DOI":"10.1038\/s41598-020-78560-3","volume":"10","author":"Z Lin","year":"2020","unstructured":"Lin Z, Huang L, Li S, Gu J, Cui X, Zhou Y. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. Sci Rep. 2020;10(1):21530. https:\/\/doi.org\/10.1038\/s41598-020-78560-3.","journal-title":"Sci Rep"},{"key":"4175_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0460","author":"MR Valentin","year":"2024","unstructured":"Valentin MR, Beatty M, Khambati F, Hall AM, Hall M, Mullinax JE, et al. 460 Enrichment of neoantigen reactive tumor infiltrating lymphocytes (TIL) in gastric cancer. J ImmunoTher Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0460.","journal-title":"J ImmunoTher Cancer"},{"issue":"6","key":"4175_CR99","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","volume":"31","author":"FJ Lowery","year":"2025","unstructured":"Lowery FJ, Goff SL, Gasmi B, Parkhurst MR, Ratnam NM, Halas HK, et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat Med. 2025;31(6):1994\u20132003. https:\/\/doi.org\/10.1038\/s41591-025-03627-5.","journal-title":"Nat Med"},{"issue":"1","key":"4175_CR100","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10238-025-01574-6","volume":"25","author":"R Shaik","year":"2025","unstructured":"Shaik R, Royyala SA, Inapanuri B, Durgam A, Khan H, Unnisa A. Tumor infiltration therapy: from FDA approval to next-generation approaches. Clin Exp Med. 2025;25(1):254. https:\/\/doi.org\/10.1007\/s10238-025-01574-6.","journal-title":"Clin Exp Med"},{"issue":"3","key":"4175_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102016","volume":"6","author":"TJ Monberg","year":"2025","unstructured":"Monberg TJ, Pakola SA, Albieri B, Ellebaek E, Donia M, Eefsen RL, et al. Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. Cell Rep Med. 2025;6(3):102016. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102016.","journal-title":"Cell Rep Med"},{"key":"4175_CR102","doi-asserted-by":"publisher","first-page":"1388475","DOI":"10.3389\/fonc.2024.1388475","volume":"14","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024;14:1388475. https:\/\/doi.org\/10.3389\/fonc.2024.1388475.","journal-title":"Front Oncol"},{"issue":"5","key":"4175_CR103","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou E, Choudhry MS, Starr TK, Folsom TD, Bell J, Rathmann B, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26(5):559\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(25)00083-X.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4175_CR104","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1016\/j.ymthe.2025.04.031","volume":"33","author":"RA Burga","year":"2025","unstructured":"Burga RA, Aksoy BA, Ao Z, Tchaicha JH, Sethi DK, Villasmil Ocando A, et al. IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Mol Ther. 2025;33(8):3605\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.031.","journal-title":"Mol Ther"},{"issue":"16 suppl","key":"4175_CR105","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1200\/JCO.2025.43.16_suppl.9517","volume":"43","author":"JA Chesney","year":"2025","unstructured":"Chesney JA, In GK, Shoushtari AN, Moyers JT, Samhouri Y, Johnson TT, et al. OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)\u2013resistant advanced melanoma: phase 1 results of the Agni-01 multicenter study. J Clin Oncol. 2025;43(16 suppl):9517. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9517.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4175_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139\u201349. https:\/\/doi.org\/10.1084\/jem.174.1.139.","journal-title":"J Exp Med"},{"key":"4175_CR107","doi-asserted-by":"publisher","first-page":"1229540","DOI":"10.3389\/fimmu.2023.1229540","volume":"14","author":"E Cappuzzello","year":"2023","unstructured":"Cappuzzello E, Vigolo E, D\u2019Accardio G, Astori G, Rosato A, Sommaggio R. How can cytokine-induced killer cells overcome CAR-T cell limits. Front Immunol. 2023;14:1229540. https:\/\/doi.org\/10.3389\/fimmu.2023.1229540.","journal-title":"Front Immunol"},{"key":"4175_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1609320","author":"W Yang","year":"2025","unstructured":"Yang W, Liu J, Hou T, Lu X, Yang L. Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1609320.","journal-title":"Front Immunol"},{"issue":"12","key":"4175_CR109","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","volume":"235","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020;235(12):9291\u2013303. https:\/\/doi.org\/10.1002\/jcp.29827.","journal-title":"J Cell Physiol"},{"key":"4175_CR110","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.jcyt.2020.03.214","volume":"22","author":"P Palmerini","year":"2020","unstructured":"Palmerini P, Cappuzzello E, Piet\u00e0 A, Sommaggio R, Astori G, Chieregato K, et al. Optimization of a gmp-grade large-scale expansion protocol for cytokine-induced killer cells using gas-permeable static culture flasks. Cytotherapy. 2020;22:S116. https:\/\/doi.org\/10.1016\/j.jcyt.2020.03.214.","journal-title":"Cytotherapy"},{"issue":"3b","key":"4175_CR111","first-page":"2237","volume":"26","author":"J Jiang","year":"2006","unstructured":"Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006;26(3b):2237\u201342.","journal-title":"Anticancer Res"},{"issue":"9","key":"4175_CR112","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jcyt.2016.05.015","volume":"18","author":"Y Mu","year":"2016","unstructured":"Mu Y, Zhou CH, Chen SF, Ding J, Zhang YX, Yang YP, et al. Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell \/dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: a systematic review and meta-analysis. Cytotherapy. 2016;18(9):1162\u201377. https:\/\/doi.org\/10.1016\/j.jcyt.2016.05.015.","journal-title":"Cytotherapy"},{"key":"4175_CR113","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5473292","author":"G Liu","year":"2022","unstructured":"Liu G, Chen D, Zhao X, You X, Huang C, Cheng Z, et al. Efficacy of DC-CIK immunotherapy combined with chemotherapy on locally advanced gastric cancer. J Oncol. 2022. https:\/\/doi.org\/10.1155\/2022\/5473292.","journal-title":"J Oncol"},{"key":"4175_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267369","author":"X Ma","year":"2023","unstructured":"Ma X, Peng L, Wang J, Gao L, Zhang W, Lu X, et al. Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1267369.","journal-title":"Front Immunol"},{"issue":"48","key":"4175_CR115","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.3748\/wjg.v16.i48.6155","volume":"16","author":"JT Jiang","year":"2010","unstructured":"Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol. 2010;16(48):6155\u201362. https:\/\/doi.org\/10.3748\/wjg.v16.i48.6155.","journal-title":"World J Gastroenterol"},{"key":"4175_CR116","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.2147\/ott.S107745","volume":"9","author":"Y Mu","year":"2016","unstructured":"Mu Y, Wang WH, Xie JP, Zhang YX, Yang YP, Zhou CH. Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized phase II study. Onco Targets Ther. 2016;9:4617\u201327. https:\/\/doi.org\/10.2147\/ott.S107745.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"4175_CR117","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1078-0432.Ccr-18-2360","volume":"25","author":"G Qiao","year":"2019","unstructured":"Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S, et al. Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: a prospective study. Clin Cancer Res. 2019;25(5):1494\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2360.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4175_CR118","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00262-012-1289-2","volume":"61","author":"L Shi","year":"2012","unstructured":"Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61(12):2251\u20139. https:\/\/doi.org\/10.1007\/s00262-012-1289-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"4175_CR119","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/cbr.2012.1306","volume":"28","author":"H Zhao","year":"2013","unstructured":"Zhao H, Fan Y, Li H, Yu J, Liu L, Cao S, et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm. 2013;28(4):303\u20139. https:\/\/doi.org\/10.1089\/cbr.2012.1306.","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"4175_CR120","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3892\/ol.2013.1281","volume":"5","author":"L Zhang","year":"2013","unstructured":"Zhang L, Hou Y, Zhang J, Hu J, Zhang K. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett. 2013;5(6):1826\u201332. https:\/\/doi.org\/10.3892\/ol.2013.1281.","journal-title":"Oncol Lett"},{"issue":"1","key":"4175_CR121","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.clim.2013.07.006","volume":"149","author":"J Huang","year":"2013","unstructured":"Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3\/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 2013;149(1):156\u201368. https:\/\/doi.org\/10.1016\/j.clim.2013.07.006.","journal-title":"Clin Immunol"},{"issue":"5","key":"4175_CR122","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jcyt.2019.03.347","volume":"21","author":"Z Zeng","year":"2019","unstructured":"Zeng Z, Zhang T, Lu Y, Liu Z, Wu D, Li Y. Study of activated CIK armed with bispecific antibody for advanced liver cancer. Cytotherapy. 2019;21(5):S30. https:\/\/doi.org\/10.1016\/j.jcyt.2019.03.347.","journal-title":"Cytotherapy"},{"issue":"3","key":"4175_CR123","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antib13030071","volume":"13","author":"S Zaninelli","year":"2024","unstructured":"Zaninelli S, Panna S, Tettamanti S, Melita G, Doni A, D\u2019Autilia F, et al. Functional activity of cytokine-induced killer cells enhanced by CAR-CD19 modification or by soluble bispecific antibody Blinatumomab. Antibodies. 2024;13(3):71.","journal-title":"Antibodies"},{"key":"4175_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102665","volume":"122","author":"CM Ying Li","year":"2024","unstructured":"Ying Li CM, Li R, Drew P, Price T, Smith E, Maddern GJ, et al. Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: current strategies and future challenges. Cancer Treat Rev. 2024;122:102665. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102665.","journal-title":"Cancer Treat Rev"},{"key":"4175_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172147","author":"KW Lee","year":"2023","unstructured":"Lee KW, Yam JWP, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12172147.","journal-title":"Cells"},{"key":"4175_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789078","volume":"11","author":"HM Maeng","year":"2021","unstructured":"Maeng HM, Moore BN, Bagheri H, Steinberg SM, Inglefield J, Dunham K, et al. Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy. Front Oncol. 2021;11:789078. https:\/\/doi.org\/10.3389\/fonc.2021.789078.","journal-title":"Front Oncol"},{"issue":"4","key":"4175_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093886","volume":"9","author":"D Gao","year":"2014","unstructured":"Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS ONE. 2014;9(4):e93886. https:\/\/doi.org\/10.1371\/journal.pone.0093886.","journal-title":"PLoS ONE"},{"key":"4175_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030090","author":"M Papakonstantinou","year":"2025","unstructured":"Papakonstantinou M, Chatzikomnitsa P, Gkaitatzi AD, Myriskou A, Giakoustidis A, Giakoustidis D, et al. The efficacy of neoantigen-loaded dendritic cell vaccine immunotherapy in non-metastatic gastric cancer. Med Sci (Basel). 2025. https:\/\/doi.org\/10.3390\/medsci13030090.","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"4175_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00279-3","volume":"6","author":"Z Guo","year":"2022","unstructured":"Guo Z, Yuan Y, Chen C, Lin J, Ma Q, Liu G, et al. Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ Precis Oncol. 2022;6(1):34. https:\/\/doi.org\/10.1038\/s41698-022-00279-3.","journal-title":"NPJ Precis Oncol"},{"key":"4175_CR130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16264","volume":"42","author":"Q Wu","year":"2024","unstructured":"Wu Q, Li Q. A pilot trial of personalized neoantigen pulsed autologous dendritic cell vaccine as adjuvant treatment in hepatocellular carcinoma. J Clin Oncol. 2024;42:e16264-e. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e16264.","journal-title":"J Clin Oncol"},{"key":"4175_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117858","volume":"184","author":"M Sheykhhasan","year":"2025","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Heidari R, Chamanara M, Akbari M, Poondla N, et al. Revolutionizing cancer treatment: the power of dendritic cell-based vaccines in immunotherapy. Biomed Pharmacother. 2025;184:117858. https:\/\/doi.org\/10.1016\/j.biopha.2025.117858.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4175_CR132","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5114\/ceji.2018.77381","volume":"43","author":"N Pu","year":"2018","unstructured":"Pu N, Zhao G, Gao S, Cui Y, Xu Y, Lv Y, et al. Neutralizing TGF-\u03b2 promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes. Cent Eur J Immunol. 2018;43(2):123\u201331. https:\/\/doi.org\/10.5114\/ceji.2018.77381.","journal-title":"Cent Eur J Immunol"},{"key":"4175_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040371","author":"Y Shen","year":"2025","unstructured":"Shen Y, Huang W, Nie J, Zhang L. Progress update on STING agonists as vaccine adjuvants. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13040371.","journal-title":"Vaccines"},{"issue":"3 suppl","key":"4175_CR134","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1200\/JCO.2021.39.3_suppl.200","volume":"39","author":"Z Bu","year":"2021","unstructured":"Bu Z, Jia Z, Ji K, Ji X, Zhang J, Wu X, et al. A phase I study to evaluate the safety of multiantigen stimulated tumor specific cell therapy (MASCT-I) in subjects with advanced gastric cancer. J Clin Oncol. 2021;39(3 suppl):200. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.200.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4175_CR135","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/s41467-025-58289-1","volume":"16","author":"I Heras-Murillo","year":"2025","unstructured":"Heras-Murillo I, Ma\u00f1anes D, Munn\u00e9 P, N\u00fa\u00f1ez V, Herrera J, Catal\u00e1-Montoro M, et al. Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse. Nat Commun. 2025;16(1):3369. https:\/\/doi.org\/10.1038\/s41467-025-58289-1.","journal-title":"Nat Commun"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04175-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:55Z","timestamp":1781873875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04175-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":135,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04175-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}